With 0.57 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.54 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $152.18 whereas the lowest price it dropped to was $148.01. The 52-week range on GKOS shows that it touched its highest point at $153.50 and its lowest point at $74.75 during that stretch. It currently has a 1-year price target of $156.69. Beta for the stock currently stands at 1.05.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GKOS was down-trending over the past week, with a drop of -1.02%, but this was up by 7.62% over a month. Three-month performance surged to 16.51% while six-month performance rose 25.48%. The stock gained 94.19% in the past year, while it has lost -0.17% so far this year. A look at the trailing 12-month EPS for GKOS yields -2.96 with Next year EPS estimates of -1.09. For the next quarter, that number is -0.38. This implies an EPS growth rate of 19.74% for this year and 40.02% for next year. EPS is expected to grow by 8.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -49.95%.
Float and Shares Shorts:
At present, 55.09 million GKOS shares are outstanding with a float of 53.13 million shares on hand for trading. On 2024-12-13, short shares totaled 2.57 million, which was 466.0 higher than short shares on 1731628800. In addition to Mr. Thomas William Burns as the firm’s Chairman & CEO, Mr. Joseph E. Gilliam serves as its President & COO.
Institutional Ownership:
Through their ownership of 1.01032 of GKOS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, GKOS reported revenue of $96670000.0 and operating income of -$24660000.0. The EBITDA in the recently reported quarter was -$7376000.0 and diluted EPS was -$0.39.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GKOS since 20 analysts follow the stock currently. There are 16 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GKOS analysts setting a high price target of 185.0 and a low target of 120.0, the average target price over the next 12 months is 153.91667. Based on these targets, GKOS could surge 23.6% to reach the target high and fall by -19.83% to reach the target low. Reaching the average price target will result in a growth of 2.83% from current levels.
Analysts have provided yearly estimates in a range of -$1.70621 being high and -$1.9954 being low. For GKOS, this leads to a yearly average estimate of -$1.82189. Based on analyst estimates, the high estimate for the next quarter is -$0.23 and the low estimate is -$0.54. The average estimate for the next quarter is thus -$0.37.
